

For Immediate Release**TSX Exchange Symbol: RVX**

Suite 202
279 Midpark Way SE
Calgary AB T2X 1M2
P 403.254.9252
F 403.256.8495
info@resverlogix.com

Resverlogix Corp. First Lead RVX-208 Raises ApoA-I up to 180%

CALGARY, AB, September 28, 2006 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX), is pleased to announce today that its first lead candidate RVX-208 has illustrated the ability to raise ApoA-I levels in animals up to 180% over controls. It is estimated that a larger than 8% permanent ApoA-I increase in humans would have a significant impact on atherosclerosis and cardiovascular disease. The Company has previously announced that it will commence first administration in microdosing human trials, early in 2007.

“RVX-208 possesses significant higher potency relative to earlier compounds from our drug discovery program. This is a further demonstration of the exciting progress in our NexVas™ PR program,” stated Don McCaffrey President and CEO of Resverlogix. “We have witnessed some major breakthroughs over the past year towards more potent and efficacious compounds. Dr. Gregory Wagner, Senior Vice President Preclinical Development, and our entire R&D team has diligently and successfully identified an optimized lead compound,” McCaffrey added.

In 2003, Esperion Therapeutics shook the medical world with its novel Recombinant ApoA-I Milano protein technology. Their clinical trial that involved 47 patients clearly illustrated that coronary atherosclerotic plaque could be reversed over five weeks by enhancing ApoA-I levels by about 10%.

“The potency of RVX-208 in animals is very encouraging and the planned first administration in man trial should position us well for rapid development of NexVas PR technology. The increase of ApoA-I by RVX-208 seen in animals should translate to humans, having the potential to radically treat human atherosclerosis disease,” stated Dr. Jan Johansson Senior Vice President Clinical Affairs. “During my 25 years in this medical area I have never been more excited. Esperion results represented an important milestone for ApoA-I technology by using intravenous infusions in the acute treatment setting. With RVX-208 being a small molecule drug for chronic treatment we anticipate ApoA-I levels to permanently increased thereby possibly radically treating atherosclerosis disease as myocardial infarcts, angina pectoris and stroke” Dr. Johansson added further.

About Resverlogix Corp.

Resverlogix is a leading biotechnology research company that is driven to develop novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to continue its focus of leading research, development and commercialization of novel therapeutics that address the risk of CVD. Through its research efforts the Company has expanded its CVD research programs to three, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR) is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI), the Company's second CVD program, is a research stage technology focused on molecular targets of vascular inflammation. ReVas™ is the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered this program with world leading medical technology company Medtronic. The company's secondary research focus program is TGF-β Shield™, a dual focused program that aims to address the unmet medical need of grievous proliferative diseases, such as cancer and fibrosis, with a TGF-β inhibitor. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and

sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Kenneth Lebioda
Senior Vice President
Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252 ext. 227
Fax: 403-256-8495
Email: ken@resverlogix.com

Theresa Kennedy
Vice President
Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Website: www.resverlogix.com